Warning

The Ultimate US Guide to Managing Medical Leaves and Accommodations Workshop (Oakland, California, United States - April 4-5, 2024)

Retrieved on: 
Thursday, January 11, 2024

As well as the implications of ADA/ FEHA and FMLA or CFRA running concurrently with other medical leaves including Workers' Compensation and your own company policies.

Key Points: 
  • As well as the implications of ADA/ FEHA and FMLA or CFRA running concurrently with other medical leaves including Workers' Compensation and your own company policies.
  • TOPIC 2: Best Practices for implementing and managing FMLA and CFRA regulations.
  • Discuss when and how CFRA regulations will run concurrently with FMLA and how your company's policy should handle those situations.
  • How to train staff on effectively managing new regulations and other leave of absences to help in the prevention of a lawsuit.

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

Retrieved on: 
Friday, October 27, 2023

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo® (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo® (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).
  • RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).
  • Together, the three retinal conditions affect around 3 million people in the U.S. and are among the leading causes of vision loss.
  • This was further supported by data showing Vabysmo achieved rapid and robust drying of retinal fluid.

Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial

Retrieved on: 
Sunday, October 22, 2023

Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.

Key Points: 
  • Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.
  • Immune-mediated adrenal insufficiency occurred in 1.5% (6/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (0.3%) adverse reactions.

IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone

Retrieved on: 
Friday, October 20, 2023

Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.

Key Points: 
  • Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.
  • Immune-mediated pneumonitis occurred in 3.5% (21/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including fatal (0.5%), and Grade 3 (1%) adverse reactions.
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.

Tesla deletes web page listing Full Self-Driving software's limitations hours after The Dawn Project links to it in press release

Retrieved on: 
Monday, July 24, 2023

Within four hours of the press release being published on over 400 news websites Tesla deleted the page from its website.

Key Points: 
  • Within four hours of the press release being published on over 400 news websites Tesla deleted the page from its website.
  • Tesla then published a new page in the Tesla Model 3's online manual for Full Self-Driving software, which no longer listed the limitations but instead linked to a new web page listing the limitations of Full Self-Driving and many other Tesla features such as Smart Summon.
  • Tesla has blocked Wayback Machine from crawling the new Limitations and Warnings page on its website, please find a PDF of the page here .
  • Dan O'Dowd, Founder of The Dawn Project, commented: "Tesla deleting this page from the website hours after it was shared with the media speaks volumes.

IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial

Retrieved on: 
Friday, June 2, 2023

These results demonstrate an increase in pathologic complete response after adding durvalumab treatment to FLOT chemotherapy and surgery.

Key Points: 
  • These results demonstrate an increase in pathologic complete response after adding durvalumab treatment to FLOT chemotherapy and surgery.
  • Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy

Retrieved on: 
Friday, May 26, 2023

Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (

Key Points: 
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.
  • Immune-mediated adrenal insufficiency occurred in 1.5% (6/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (0.3%) adverse reactions.
  • In patients with extensive-stage SCLC in the CASPIAN study receiving IMFINZI plus chemotherapy (n=265), IMFINZI was discontinued due to adverse reactions in 7% of the patients receiving IMFINZI plus chemotherapy.

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

Retrieved on: 
Sunday, April 16, 2023

Grade 3/4 any-cause adverse events occurred in 42.3% of patients treated with the IMFINZI-based regimen versus 43.4% for chemotherapy alone.

Key Points: 
  • Grade 3/4 any-cause adverse events occurred in 42.3% of patients treated with the IMFINZI-based regimen versus 43.4% for chemotherapy alone.
  • Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month.
  • Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.
  • AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer

Retrieved on: 
Thursday, March 9, 2023

The trial will continue as planned to assess key secondary endpoints including disease-free survival (DFS) and overall survival (OS).

Key Points: 
  • The trial will continue as planned to assess key secondary endpoints including disease-free survival (DFS) and overall survival (OS).
  • We have shown that adding IMFINZI both before and after surgery significantly increased the time patients live without recurrence or progression events.
  • AstraZeneca has a comprehensive portfolio of approved and potential new medicines in development for patients with lung cancer.
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (

Surgical Innovation Associates (SIA) Announces Definitive Agreement to be Acquired by Integra LifeSciences

Retrieved on: 
Thursday, December 1, 2022

Surgical Innovation Associates (SIA) today announced that it entered into a definitive agreement to be acquired by Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company.

Key Points: 
  • Surgical Innovation Associates (SIA) today announced that it entered into a definitive agreement to be acquired by Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company.
  • The transaction is expected to close by the end of the year, subject to the satisfaction of customary conditions.
  • Today, there are no surgical matrices approved by the FDA specifically for use in implant-based breast reconstruction (IBBR) for mastectomy patients.
  • Integra is the only manufacturer so far to submit a premarket approval (PMA) application for this soft tissue support in IBBR.